Review Articles
Vol. 2 No. 2 (2010): New Drugs and Hemopoietic Stem Cell Transplantation in Oncohematological Diseases of the Elderly
https://doi.org/10.4084/mjhid.2010.011

APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: May 7, 2010
4065
Views
640
Downloads
2424
HTML
Chronic Lymphoid Leukemia, New Drugs, nucleoside analogs, Flavopiridol, lenalidomide, rituximab, Anti-CD23

Authors

Tadeusz Robak
robaktad@csk.umed.lodz.pl
Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland, Italy.
Over the last few years, several new agents have been under evaluation in preclinical studies as well as in early clinical trials, and have shown promise in treating CLL. These treatments include new  monoclonal antibodies (mAbs), immunomodulating agents, novel purine nucleoside analogs, Bcl-2 inhibitors and other agents. The most promising are a new mAbs targeted CD20 molecule or CD23, anti-CD40 mAbs and anti-CD37 antibody. Oblimersen , flavopiridol, and lenalidomide are also being evaluated both in pre-clinical studies and in early clinical trials. However,  available therapies are only partially efficient and there is an obvious need to develop better strategies and new, more specific and active drugs

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Tadeusz Robak, Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital,  Lodz, Poland

How to Cite



“APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA” (2010) Mediterranean Journal of Hematology and Infectious Diseases, 2(2), p. e2010011. doi:10.4084/mjhid.2010.011.